Drugs / Ganitumab
Trials 28
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 15 trials | ||||||
| Phase 1 | NCT01298401 | Feb 2012 → Nov 2013 | malignant pancreatic neoplasm | Radiation Therapy Oncology Group | Completed | No outcome recorded |
| Phase 1 | NCT01122199 | May 2010 → Jan 2015 | metastatic neoplasm | Shadia Jalal | Completed | No outcome recorded |
| Phase 1 | NCT01061788 | Apr 2010 → Dec 2018 | non-small cell lung carcinoma | Jeffrey Clarke | Completed | No outcome recorded |
| Phase 1 | NCT00974896 | Dec 2006 → Sep 2010 | cancer | NantCell, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT00562380 | Oct 2005 → Apr 2010 | cancer of unknown primary site, lymphoma, prostate cancer, sarcoma +1 | Amgen | Completed | No outcome recorded |
| Phase 1/29 trials | ||||||
| Phase 1/2 | NCT03041701 | Jul 2017 → Sep 2021 | alveolar rhabdomyosarcoma, embryonal rhabdomyosarcoma | National Cancer Institute (NCI) | Terminated | No outcome recorded Stop: Enrollment |
| Phase 1/2 | NCT01708161 | Nov 2012 → Dec 2014 | — | Novartis Pharmaceuticals | Terminated | No outcome recorded |
| Phase 1/2 | NCT01479179 | Nov 2012 → Nov 2015 | breast cancer | M.D. Anderson Cancer Center | Withdrawn | No outcome recorded Stop: Business |
| Phase 1/2 | NCT01562899 | Aug 2012 → Apr 2015 | pancreatic adenocarcinoma | Pfizer | Terminated | No outcome recorded Stop: Business |
| Phase 1/2 | NCT01473303 | Aug 2012 | pancreatic ductal adenocarcinoma | Alliance for Clinical Trials in Oncology | Withdrawn | No outcome recorded |
| Phase 1/2 | NCT00807612 | Jan 2009 → Aug 2010 | non-small cell squamous lung carcinoma | NantCell, Inc. | Terminated | No outcome recorded |
| Phase 1/2 | NCT00791154 | Dec 2008 → Feb 2010 | small cell lung carcinoma | NantCell, Inc. | Terminated | No outcome recorded |
| Phase 1/2 | NCT00788957 | Oct 2008 → Jul 2010 | colon carcinoma, rectal cancer | NantBioScience, Inc. | Completed | No outcome recorded |
| Phase 1/2 | NCT00630552 | Jun 2007 → Jan 2010 | pancreatic adenocarcinoma | NantCell, Inc. | Completed | No outcome recorded |
| Phase 210 trials · 1 met primary · 1 missed | ||||||
| Phase 2 | NCT04129151 | Dec 2019 → Dec 2022 | Ewing sarcoma | Dana-Farber Cancer Institute | Terminated | Missed primary |
| Phase 2 | NCT01318642 | May → Nov 2012 | pancreatic adenocarcinoma | NantBioScience, Inc. | Terminated | No outcome recorded |
| Phase 2 | NCT01327612 | Mar 2011 → Feb 2020 | carcinoid tumor, colorectal cancer, lymphoma, metastatic malignant neoplasm +2 | Amgen | Completed | No outcome recorded |
| Phase 2 | NCT01042379 | Mar 2010 → Dec 2030 expected | HER2 positive breast carcinoma, angiosarcoma, female breast carcinoma, hormone receptor-positive breast cancer +1 | QuantumLeap Healthcare Collaborative | Recruiting | No outcome recorded |
| Phase 2 | NCT01024387 | Mar 2010 → Jan 2016 | carcinoid tumor, pancreatic neuroendocrine tumor | Dana-Farber Cancer Institute | Completed | No outcome recorded |
| Phase 2 | NCT00891930 | May 2009 → Jul 2013 | colorectal cancer | NantBioScience, Inc. | Completed | Met primary |
| Phase 2 | NCT00813605 | Mar 2009 → Jan 2011 | colorectal cancer | NantCell, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT00718523 | Jan 2009 → Sep 2013 | ovarian neoplasm | Translational Research in Oncology | Terminated | No outcome recorded |
| Phase 2 | NCT00719212 | Jan 2009 → May 2013 | ovarian neoplasm | Translational Research in Oncology | Completed | No outcome recorded |
| Phase 2 | NCT00563680 | Oct 2007 → Aug 2009 | Askin tumor, desmoplastic small round cell tumor, extraskeletal Ewing sarcoma | NantCell, Inc. | Completed | No outcome recorded |
| Phase 32 trials · 1 missed | ||||||
| Phase 3 | NCT02306161 | Dec 2014 → Mar 2021 overdue | Ewing sarcoma, metastatic malignant neoplasm, peripheral primitive neuroectodermal tumor of bone, peripheral primitive neuroectodermal tumor of soft tissues | National Cancer Institute (NCI) | Active not recruiting | Missed primary |
| Phase 3 | NCT01231347 | Apr 2011 → Dec 2012 | malignant endocrine neoplasm, metastatic carcinoma in the bone, pancreatic adenocarcinoma | NantCell, Inc. | Completed | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT04199026 | Feb 2025 → Dec 2028 expected | sarcoma | M.D. Anderson Cancer Center | Recruiting | No outcome recorded |
| Phase not stated1 trial | ||||||
| — | NCT03029481 | — | Ewing sarcoma | Jonsson Comprehensive Cancer Center | No longer available | No outcome recorded |
| Comparator or background therapy2 trials | ||||||
| Phase 1/2 | NCT00819169 Background | Jan 2009 → Aug 2011 | colorectal cancer, malignant pancreatic neoplasm, metastatic malignant neoplasm, non-small cell lung carcinoma +2 | NantCell, Inc. | Terminated | No outcome recorded Stop: Business |
| Phase 2 | NCT00626106 Comparator | Mar 2008 → May 2010 | female breast carcinoma, metastatic malignant neoplasm | NantCell, Inc. | Completed | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 30 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ganitumab | “for AMG479 (ganitumab) and RAD001 (everolimus).” NCT01122199 ↗ |
| Known as | AMG 479 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00791154 ↗ |
| Action | Inhibit | “AMG 479 inhibits the binding of both IGF-1 and IGF-2 to IGF-1R, thus inhibiting ligand-dependent receptor activation.” NCT00563680 ↗ |
| Modality | Monoclonal antibody | “fully human monoclonal antibody (IgG1)” NCT00563680 ↗ |
| Route | Intravenous | “Arm A: AMG 479 12 mg/kg IV Q2W + Endocrine Therapy” NCT00626106 ↗ |
| Target | IGF1R | “targeted against insulin-like growth factor receptor type 1 (IGF-1R)” NCT00630552 ↗ |